When Were Insulin Pumps Invented? A Brief History

The first insulin pump prototypes appeared in the 1960s, but the technology took roughly two decades to move from experimental curiosity to something a person could actually wear at home. A 1963 device built by endocrinologist Arnold Kadish was about the size of a backpack and far too bulky for daily life. The real breakthrough came in the late 1970s, when researchers in London showed that a miniature, battery-driven syringe pump worn on the body could keep blood sugar near normal levels for days at a time. From that point forward, the insulin pump has been reinvented over and over, each generation smaller, smarter, and more automated than the last.

From Backpack to Belt Clip

Kadish’s 1963 prototype proved a concept: a machine could deliver insulin continuously rather than through periodic injections, more closely mimicking how a healthy pancreas works. But the device was impractical for anything outside a research lab. Through the late 1960s and into the 1970s, several groups worked on shrinking the hardware. Dean Kamen, better known today for inventing the Segway, designed a wearable infusion pump in the mid-1970s that could deliver precise, programmable doses of medication. These early devices set the engineering stage, but the clinical question remained unanswered: would pumping insulin under the skin actually improve blood sugar control?

In 1978, a team led by John Pickup at Guy’s Hospital in London published a pivotal study addressing exactly that. They fitted twelve people with type 1 diabetes with a miniature syringe pump that infused insulin through a fine nylon tube inserted under the skin. The pump ran at a steady basal rate and was stepped up before meals. The results suggested that this continuous subcutaneous insulin infusion, or CSII, could maintain near-normal glucose levels, something that multiple daily injections often struggled to achieve.¹

A year later, in 1979, the same research group took the next critical step: they sent people home with the pumps. Six insulin-requiring patients used portable syringe pumps in their everyday lives for periods ranging from 48 to 111 days, demonstrating that the technology was not just a hospital trick but something that could function in the real world.² This transition from bedside experiment to home therapy marked the true beginning of insulin pump therapy as we know it.

The Rough 1980s

The first commercially available insulin pumps hit the market in the early 1980s. These were simple devices by today’s standards: a battery-powered motor, a syringe, and a length of tubing ending in a small needle or cannula taped to the abdomen. They offered programmable basal rates and the ability to deliver a bolus of insulin before eating, which was a massive improvement over the rigid schedules that came with injections. But the technology was far from polished.

Early pumps were bulky, their alarms were unreliable, and the infusion sets were prone to kinking or dislodging. More concerning was the safety profile. Data spanning four decades show that pump use in the 1980s was associated with a dramatically higher risk of diabetic ketoacidosis, a dangerous buildup of acids in the blood that occurs when insulin delivery is interrupted. The risk during that era was roughly six times higher for pump users compared to those on injections. By the 2010s, improvements in pump design, infusion sets, and user education had effectively eliminated that excess risk.³ That trajectory says a lot about how much the hardware and the clinical support around it have matured.

Despite the rocky start, the 1980s established the pump as a legitimate treatment option. Clinicians began recognizing which patients benefited most: those with widely fluctuating blood sugars, people whose work schedules made fixed injection times impractical, and anyone who needed fine-tuned dosing that syringes couldn’t easily deliver. The Diabetes Control and Complications Trial (DCCT), which enrolled participants starting in 1983 and published landmark results in 1993, powerfully reinforced the value of tight glucose control, lending momentum to any tool that could help achieve it.

Pumps Meet Glucose Sensors

For roughly two decades, insulin pumps operated blind. They delivered insulin according to a pre-programmed schedule and whatever the user dialed in at mealtimes, but they had no idea what the person’s blood sugar was actually doing between finger sticks. That changed in the mid-2000s with the arrival of continuous glucose monitors, small sensors worn on the body that measure glucose levels every few minutes. Once manufacturers started building pumps that could receive data from these sensors, an entirely new category of device emerged.

Sensor-augmented pump therapy combined continuous glucose monitoring with insulin delivery in a single system. The sensor data appeared on the pump’s screen, giving users a real-time picture of where their glucose was headed. This was described as a major building block toward the artificial pancreas, a system that could eventually adjust insulin delivery on its own without human input.⁴

Early randomized trials tested whether this combination actually outperformed a pump alone. In one of the first treat-to-target studies, researchers compared a pump paired with real-time glucose monitoring against a pump with standard finger-stick testing to see if the added sensor data translated into better outcomes.⁵ A larger trial published in the New England Journal of Medicine in 2010 provided stronger evidence. In that study, adults and children with type 1 diabetes who used sensor-augmented pump therapy saw their average blood sugar marker (HbA1c) drop from about 8.3% to 7.5% over a year, compared with a drop to only 8.1% in those using injections. Critically, this improvement came without increasing episodes of severe low blood sugar.⁶

Sensor-augmented pumps also introduced the first glimmer of automation. Medtronic’s system, for instance, could suspend insulin delivery when the sensor detected glucose was dropping toward a dangerous low, then resume when levels recovered. It wasn’t a fully automated system, but it was the first time a pump made a dosing decision without human input.

Cutting the Cord

Traditional insulin pumps use a length of thin tubing to connect the pump body, which clips to a belt or sits in a pocket, to the infusion site on the skin. The tubing works, but it catches on doorknobs, gets tangled during sleep, and makes the pump visible under clothing. Tubeless pumps addressed all of those complaints by packaging the reservoir, motor, and cannula into a single adhesive pod stuck directly to the skin.

The most widely known tubeless system is the Omnipod, made by Insulet Corporation. The Omnipod DASH, cleared by the FDA in the late 2010s, holds up to 200 units of insulin in a small waterproof pod controlled wirelessly by a handheld touchscreen device.⁷ Users change the pod every two to three days. The absence of tubing makes the system more discreet and, for many people, more comfortable during exercise, swimming, or sleep.

Insulet later released the Omnipod 5, which added automated insulin delivery. Real-world European data on adults transitioning to the Omnipod 5 from injections or older open-loop patch pumps showed meaningful improvements: HbA1c dropped from 7.5% to 7.1%, and the amount of time spent in the target glucose range rose from about 59% to 68%, all without an increase in low blood sugar episodes.⁸ Other companies have entered the tubeless market as well. The Medtrum A8 TouchCare, another tubeless automated system, uses an algorithm that adjusts basal insulin and delivers automatic correction doses, and has shown similar glycemic improvements in real-world use.⁹

Closing the Loop

The concept of a “closed-loop” system, sometimes called an artificial pancreas, has been the holy grail of insulin pump development since the technology’s earliest days. The idea is straightforward: a glucose sensor feeds data to an algorithm, which tells the pump how much insulin to deliver, with minimal input from the person wearing it. In practice, building a system that does this safely and reliably took decades of sensor accuracy improvements, algorithm development, and regulatory navigation.

Today, several hybrid closed-loop systems are commercially available. They are called “hybrid” because they still require the user to announce meals and enter carbohydrate estimates; the algorithm handles the rest, adjusting basal rates every few minutes and delivering automatic corrections when glucose drifts high. The evidence supporting these systems has grown substantially as more devices have reached the market.¹⁰

The evolution of these devices over the past several decades, from syringes and manual pumps through connected pens, tethered and patch pumps, and now to automated delivery systems, represents one of the most dramatic arcs in medical device history.¹¹ Each generation solved problems that the previous one created: early pumps solved the rigidity of injections but introduced ketoacidosis risks; sensor integration solved the blindness of standalone pumps but added cost and complexity; automation solved the burden of constant manual adjustment but introduced new questions about algorithm transparency and cybersecurity.

When Patients Built Their Own

Not everyone waited for manufacturers to close the loop. Starting around 2013, a community of technically skilled people with type 1 diabetes began building their own automated insulin delivery systems using off-the-shelf pumps, continuous glucose monitors, and open-source software running on a small computer like a Raspberry Pi. The most prominent project, OpenAPS (Open Artificial Pancreas System), was launched by Dana Lewis and Scott Leibrand, who were frustrated by how slowly commercial closed-loop systems were reaching the market.

By the time commercial hybrid closed-loop devices became widely available, thousands of individuals worldwide were already using DIY closed-loop systems. These homemade setups work on the same principle as commercial systems, automatically adjusting insulin delivery based on sensor data, but they differ in their transparency, customizability, and the fact that users can tweak the algorithm to suit their own bodies.¹² The code is publicly available for anyone to inspect, modify, or improve.

The DIY movement unsettled some regulators and clinicians, who worried about the safety of unapproved medical devices. But it also pushed the industry forward. Several design ideas that originated in the DIY community, like more aggressive overnight automation and remote monitoring by caregivers, later appeared in commercial products. Analysis of social media conversations among OpenAPS users suggested widespread reports of improved blood sugar control and quality of life.¹³ Whether you view DIY looping as reckless self-experimentation or as patient empowerment probably depends on how comfortable you are with the idea that users sometimes understand their own disease better than the regulatory timeline allows for.

Beyond Blood Sugar Numbers

One of the less-discussed aspects of insulin pump history is how profoundly the technology affects everyday life beyond glucose readings. Managing type 1 diabetes with injections means planning meals around dosing schedules, carrying supplies, and performing visible medical tasks in public. Pumps don’t eliminate those burdens entirely, but they reduce them enough to matter.

Studies comparing pump users to people on injection therapy consistently find higher quality-of-life scores across multiple dimensions. In one study, pump users reported better self-esteem, less stress, improved mood, greater meal flexibility, and easier travel compared to those not using pumps. They also participated more actively in social and recreational activities.¹⁴ Surveys of tubeless pump users tell a similar story: roughly three-quarters reported feeling more in control of their diabetes, and about half said they felt safer from dangerous low blood sugar episodes. About two-thirds reported actual improvements in their glucose control after switching.¹⁵

These findings help explain why, despite the cost and hassle of wearing a device around the clock, most people who try a pump choose to stay on one. The psychological relief of not having to think about basal insulin, of being able to eat spontaneously, and of sleeping without fear of an undetected low can be as valuable as the clinical improvements.

Who Gets Access

Insulin pumps have never been cheap. A standard pump system costs several thousand dollars, and supplies like infusion sets, reservoirs, and sensors add ongoing expenses. In the United States, insurance coverage varies enormously depending on the plan, and the gaps are not random. Research has found that more generous insurance coverage is strongly associated with pump use, and socioeconomic status interacts with technology access in complex ways.¹⁶

Globally, the disparity is starker. In many low- and middle-income countries, even basic insulin can be difficult to obtain, let alone a pump costing thousands of dollars plus consumables. The newest automated delivery systems, which represent the cutting edge, remain concentrated in wealthy countries with robust insurance systems. This means the history of insulin pump technology is also a story about inequality: each advance has widened the gap between what is possible for the well-insured and what is available to everyone else. Open-source projects like OpenAPS have tried to narrow that gap somewhat by reducing the cost of automation, but they still require access to a compatible pump and sensor, which are themselves expensive.

Dual-Hormone Systems and What Comes Next

Current closed-loop systems deliver only insulin, which handles high blood sugar but can’t actively raise glucose when it drops too low. The body’s natural solution involves a second hormone, glucagon, released by the pancreas to push glucose up. A dual-hormone artificial pancreas would deliver both insulin and glucagon, more closely replicating normal physiology.¹⁷

Early clinical trials have tested this approach. In a randomized crossover trial, a dual-hormone closed-loop system kept participants’ glucose in the target range about 71% of the time, compared to about 57% under conventional pump therapy. More striking was the reduction in low blood sugar: time spent below the danger threshold dropped to essentially zero during the dual-hormone sessions, versus nearly 3% of the time under conventional treatment.¹⁸ Separate work has directly compared single-hormone and dual-hormone configurations to understand whether the added complexity of a second hormone is worth it.¹⁹

The engineering challenges are real. Glucagon is chemically unstable in liquid form and needs to be reconstituted or stored differently from insulin, which complicates pump design. Newer formulations of stable glucagon are in development, and ultra-rapid insulin analogs that act faster than current formulations could make single-hormone systems more effective as well, potentially reducing the need for a second hormone altogether. Both paths are being pursued simultaneously.

The Cybersecurity Question

As pumps became wireless and internet-connected, they inherited the vulnerabilities of any networked device. Modern pumps communicate with glucose sensors, smartphone apps, and cloud platforms using Bluetooth and other wireless protocols. Researchers have demonstrated that these communication channels can, in principle, be intercepted or manipulated by unauthorized agents. The threat is not theoretical: security researchers have simulated unauthorized access to connected diabetes devices, raising concerns about the possibility of someone remotely altering insulin delivery.²⁰

Interestingly, some of the same hacking techniques have been used constructively. The DIY looping community essentially reverse-engineered the wireless communication protocols of commercial pumps to build their own closed-loop systems. This dual nature of device hacking, both a security risk and a source of patient-driven innovation, has forced manufacturers and regulators to think differently about how they design and certify connected medical devices. The FDA now requires cybersecurity risk assessments as part of the approval process for new pumps, and manufacturers have moved toward encrypted communication and more secure firmware update mechanisms. No real-world malicious attack on an insulin pump has been publicly documented, but the theoretical risk has shaped how every modern pump communicates with the devices around it.